Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

NICE issues interventional procedures guidance on use of liposuction 

The National Institute for Health and Care Excellence (NICE)'s independent committee has called for more research to ensure liposuction for treatment of chronic lipoedema is safe and effective enough for use on the NHS.

The cause of lipoedema is unknown, but hormonal changes, weight gain and genetics are thought to be involved. The size and shape of legs, and the resultant mobility issues and pain, can have a profoundly negative effect on quality of life, and physical and mental health.

The interventional procedures advisory committee reviewed evidence from several sources, including eight before-and-after studies. The committee was informed that several different liposuction techniques are used and that they may have different safety and efficacy profiles.

From the evidence presented, the committee believed that the evidence on the safety of the procedure is inadequate and also raises concerns of major adverse events such as fluid imbalance, fat embolism, deep vein thrombosis, and toxicity from local anaesthetic agents. The evidence on the efficacy of the procedure is also inadequate, based mainly on retrospective studies with methodological limitations.

However, evidence from a randomised controlled trial currently taking place in Germany could provide better evidence in support of the use of liposuction for the treatment of chronic lipoedema.

NICE will review its guidance upon the publication of evidence from the German trial.

Jeanette Kusel, interim director of MedTech and digital at NICE, said: “The committee’s focus is to ensure that procedures are safe enough and work well enough to be used by surgeons in the NHS. On this occasion the published evidence is not strong enough which is why they have called for further research.

“We know many people with this painful and debilitating condition will be disappointed by this decision. Patient groups have actively engaged with this topic throughout the appraisal process and put forward a strong case for a positive recommendation because there are very few treatment options.

“We would like to make a more positive recommendation, but we cannot compromise on safety. The committee hopes that a randomised controlled trial currently taking place in Germany will provide them with the high-quality evidence they need. Once the study has reported its findings, we will review our guidance.”

NICE interventional procedures guidance applies to the whole of the United Kingdom.

More For You

Air pollution in UK linked to thousands of deaths and chronic health conditions

A report by the Royal College of Physicians claims that air pollution was causing harm to almost every organ of the body.

iStock

Royal College of Physicians paints grim picture of air pollution in UK

Doctors warn that around 99 per cent of the population in the UK are breathing "toxic air", and around 30,000 deaths will be linked to air pollution in 2025.

The Royal College of Physicians (RCP) claimed in a report that air pollution was causing harm to almost every organ of the body, and shortening life by 1.8 years on average.

Keep ReadingShow less
Community pharmacies falling behind on data security toolkit submissions

The last date for submission is 30 June 2025.

Pic credit: iStock

Community pharmacies falling behind on data security toolkit submissions

More than 50 per cent of the community pharmacies in England have failed to complete their Data Security and Protection Toolkit 2025 with the deadline in less than two weeks.

Necessary guidance regarding the toolkit has previously been provided by Community Pharmacy England (CPE) earlier.

Keep ReadingShow less
Digital guide launched to help patients with osteoporosis

In the UK, over three million people have osteoporosis.

Pic credit: iStock

Digital guide launched to help patients with osteoporosis

The Royal Osteoporosis Society (ROS) has launched a free online service called BoneMed which is aimed to support patients with osteoporosis in taking their medicine and remove barriers to adherence.

After completing a five-minute online survey, patients will be emailed a summary of the medicine they have been prescribed and six further updates throughout the year on their medication.

Keep ReadingShow less
GPhC five-year plan to empower pharmacists, uphold public trust

GPhC's Strategic Plan 2025-30 will focus on empowering pharmacists and pharmacy technicians.

iStock

GPhC five-year plan to empower pharmacists, uphold public trust

The General Pharmaceutical Council (GPhC) launched its new plan for the next five years to uphold safety, quality and public trust in pharmacy.

The regulatory body unveiled its Strategic Plan 2025-30 during a Parliamentary event attended by pharmacy minister Stephen Kinnock on Wednesday (18).

Keep ReadingShow less
Glucose monitor and test strips on a blood sugar tracker sheet with lancets and pen device.

Medical device manufacturers will have to monitor the safety and performance of their products already in use.

iStock

Medical device regulation overhauled to improve patients' safety

Medical device manufacturers must now adhere to the UK's post-market surveillance (PMS) regulations.

The new rule came into effect on June 16, and manufacturers will have to monitor the safety and performance of their products already in use.

Keep ReadingShow less